YolTech Gene Editing Trial Shows Promise for One-Time AATD Cure
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A gene editing trial conducted by YolTech is showing promise as a potential one-time cure for alpha-1 antitrypsin deficiency (AATD). The trial's results indicate a possible cure for the condition. The outcome of the trial suggests a positive development in the treatment of AATD.